Earnings Outlook For Axogen
On Thursday, October 29, Axogen (NASDAQ: AXGN) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.What Are Earnings, Net Income, And Earnings Per Share? Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.Earnings And Revenue Analysts are predicting Axogen will report a loss of $0.16 per share on revenue of $24.52 million. Axogen EPS in the same period a year ago totaled $0.07. Revenue was $28.56 million.What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.View more earnings on AXGNThe analyst consensus estimate would represent a 128.57% decrease in the company's earnings. Sales would be down 14.16% from the year-ago period. Here is how the company's reported EPS has compared to analyst estimates in the past:Quarter Q2 2020 Q1 2020 Q4 2020 Q3 2019 EPS Estimate -0.38 -0.15 -0.09 -0.11 EPS Actual -0.15 -0.19 -0.10 -0.07 Revenue Estimate 13.15 M 26.19 M 29.23 M 28.31 M Revenue Actual 22.12 M 24.26 M 28.16 M 28.56 M Stock Performance Shares of Axogen were trading at $12.54 as of October 27. Over the last 52-week period, shares are down 3.9%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.Do not be surprised to see the stock move on comments made during its conference call. Axogen is scheduled to hold the call at 16:30:00 ET and can be accessed here.See more from Benzinga * Click here for options trades from Benzinga * Benzinga's Top Upgrades, Downgrades For October 23, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 10h ago
The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus.
Benzinga · 3d ago
AxoGen Struggling Through A Protracted Restructuring
COVID-19 has complicated a sales restructuring effort that was already severely testing the patience of investors, as the company looks to refocus on its core trauma opportunity.Clinical data for AxoGen's key Avance product remain quite strong, showing equal-to-better efficacy compared to allografts and superiority to manufactured conduits.Results from RECON could help the sales effort, but that's at least two years from now, and AxoGen must grow its business beyond its core high-use base.AxoGen isn't the first small-cap med-tech to struggle commercializing a disruptive technology; the shares still look undervalued, but execution risk is very high.
Seekingalpha · 10/02 06:34
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors
Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of DirectorsALACHUA, Fla., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today
GlobeNewswire · 09/30 21:01
Axogen, Inc. to Present at the JMP Securities MedTech Bio Summit
ALACHUA, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JMP Securities
GlobeNewswire · 09/25 12:00
Axogen to Participate in the 75th Annual American Society for Surgery of the Hand Meeting
New data highlights the clinical and economic value of Avance® Nerve Graft compared to nerve autograftALACHUA, Fla., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves
GlobeNewswire · 09/24 12:00
Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers
Gainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%.
Seekingalpha · 09/16 15:00
Axogen, Inc. to Present at the Cantor Virtual Global Healthcare Conference
ALACHUA, Fla., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Cantor Virtual
GlobeNewswire · 08/31 12:00
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 23:45
Axogen, Inc. Reports Second Quarter 2020 Financial Results
ALACHUA, Fla., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quart
GlobeNewswire · 08/05 20:01
Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/29 16:33
Axogen, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
ALACHUA, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and pre
GlobeNewswire · 07/29 11:00
BioNTech COVID-19 Progress, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/23 14:43
Axogen concludes enrollment in late-stage nerve graft study
Axogen (NASDAQ:AXGN) has completed patient enrollment in its Phase 3 (RECON) study for Avance Nerve Graft. The 220-subject study compares the graft to manu
seekingalpha · 07/22 18:31
Axogen RECON Clinical Study Completes Target Enrollment Of 220 Subjects
ALACHUA, Fla., July 22, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that
Benzinga · 07/22 11:08
Axogen RECON Clinical Study Completes Target Enrollment of 220 Subjects
RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve GraftALACHUA, Fla., July 22, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions
GlobeNewswire · 07/22 11:00
Axogen, Inc. to Report Second Quarter 2020 Financial Results and Host Conference Call on August 5, 2020
ALACHUA, Fla., July 15, 2020 -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral.
GlobeNewswire · 07/15 11:00
Is AxoGen, Inc. (AXGN) Going to Burn These Hedge Funds?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter
Insider Monkey · 07/08 22:41
Axogen Announces New Seven-Year Financing Agreement with Oberland Capital and Provides Preliminary Second Quarter Revenue Estimate
GlobeNewswire · 07/01 12:00
Axogen initiates new seven-year financing agreement with Oberland Capital
Seeking Alpha - Article · 07/01 11:28
Webull provides a variety of real-time AXGN stock news. You can receive the latest news about Axogen Inc. through multiple platforms. This information may help you make smarter investment decisions.
AxoGen, Inc. offers surgical solutions for peripheral nerve injuries. The Company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers the AxoTouch Two-Point Discriminator, and AcroVal Neurosensory and Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation; assessing return of sensory, grip and pinch function; evaluating treatment interventions, and providing feedback to patients on nerve function. Its portfolio of products is available in the United States, Canada, the United Kingdom and several European and other countries. The Company's products are used by surgeons during surgical interventions to repair a range of nerve injuries throughout the body.More